Treatment Trials

4 Clinical Trials for Various Conditions

Focus your search

      WITHDRAWN
      Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma
      Description

      This phase II clinical trial studies how well giving brentuximab vedotin together with pembrolizumab in treating patients with peripheral T-cell lymphoma (PTCL) that has come back (recurrent). Monoclonal antibody-drug conjugates, such as brentuximab vedotin, can block cancer growth in different ways by targeting certain cells. Pembrolizumab is an antibody-drug that stimulates body's natural antitumor immune responses. Giving brentuximab vedotin together with pembrolizumab may work better than brentuximab vedotin alone in treating patients with recurrent peripheral T-cell lymphoma.

      Conditions
      Recurrent Angioimmunoblastic T-Cell LymphomaRecurrent Enteropathy-Associated T-Cell LymphomaRecurrent Follicular T-Cell LymphomaRecurrent Hepatosplenic T-Cell LymphomaRecurrent Nodal Peripheral T-Cell Lymphoma With TFH PhenotypeRecurrent Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Subcutaneous Panniculitis-Like T-Cell LymphomaRefractory Angioimmunoblastic T-Cell LymphomaRefractory Enteropathy-Associated T-Cell LymphomaRefractory Follicular T-Cell LymphomaRefractory Hepatosplenic T-Cell LymphomaRefractory Nodal Peripheral T-Cell Lymphoma With TFH PhenotypeRefractory Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedRefractory Subcutaneous Panniculitis-Like T-Cell Lymphoma
      Talk to us
      ACTIVE_NOT_RECRUITING
      Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas
      Description

      This phase I/II trial studies the side effects and best dose of pralatrexate when given together with pembrolizumab and how well they work in treating patients with peripheral T-cell lymphomas that has come back after a period of improvement or has not responded to treatment. Pralatrexate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab and pralatrexate may work better in treating patients with peripheral T-cell lymphomas.

      Conditions
      Anaplastic Large Cell LymphomaNodal Peripheral T-Cell Lymphoma With TFH PhenotypeRecurrent Anaplastic Large Cell LymphomaRecurrent Angioimmunoblastic T-Cell LymphomaRecurrent Enteropathy-Associated T-Cell LymphomaRecurrent Follicular LymphomaRecurrent Hepatosplenic T-Cell LymphomaRecurrent Mature T- Cell and NK-Cell Non-Hodgkin LymphomaRecurrent Monomorphic Epitheliotropic Intestinal T-cell LymphomaRecurrent Mycosis FungoidesRecurrent Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedRefractory Anaplastic Large Cell LymphomaRefractory Angioimmunoblastic T-Cell LymphomaRefractory Enteropathy-Associated T-Cell LymphomaRefractory Follicular LymphomaRefractory Hepatosplenic T-Cell LymphomaRefractory Mature T-Cell and NK-Cell Non-Hodgkin LymphomaRefractory Mycosis FungoidesRefractory Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedSubcutaneous Panniculitis-Like T-Cell Lymphoma
      Talk to us
      TERMINATED
      Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma
      Description

      RATIONALE: Everolimus and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of everolimus when given together with bortezomib in treating patients with relapsed or refractory lymphoma.

      Conditions
      714leukemiaLymphoma
      Talk to us
      RECRUITING
      Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency
      Description

      This partially randomized clinical trial studies cholecalciferol in improving survival in patients with newly diagnosed cancer with vitamin D insufficiency. Vitamin D replacement may improve tumor response and survival and delay time to treatment in patients with cancer who are vitamin D insufficient.

      Conditions
      Aggressive Non-Hodgkin LymphomaAnaplastic Large Cell LymphomaAngioimmunoblastic T-Cell LymphomaChronic Lymphocytic LeukemiaDiffuse Large B-Cell LymphomaEnteropathy-Associated T-Cell LymphomaHepatosplenic T-Cell LymphomaMature T-Cell and NK-Cell Non-Hodgkin LymphomaMediastinal (Thymic) Large B-Cell LymphomaNasal Type Extranodal NK/T-Cell LymphomaPeripheral T-Cell Lymphoma, Not Otherwise SpecifiedPrimary Cutaneous Anaplastic Large Cell LymphomaRefractory Anaplastic Large Cell LymphomaSmall Lymphocytic LymphomaSubcutaneous Panniculitis-Like T-Cell Lymphoma
      Talk to us